Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05086705 · ClinicalTrials.gov registry record · NA

EMBr Wave for the Reduction of Hot Flashes in Women With a History of Breast Cancer

A NA study of Breast Carcinoma and Hot Flashes, sponsored by Ohio State University Comprehensive Cancer Center.

Completed
Registry status
NA
Development phase
50
Enrollment target
1
Study location

NCT05086705: Completed NA study of Breast Carcinoma and Hot Flashes, sponsored by Ohio State University Comprehensive Cancer Center.

NCT05086705 is a NA study of Breast Carcinoma and Hot Flashes that has completed, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 50 participants, below the 770-participant average among 106 other Breast Carcinoma trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05086705, a NA study of Breast Carcinoma and Hot Flashes, has completed, sponsored by Ohio State University Comprehensive Cancer Center.

COMPLETED
Registry status
NA
Development phase
50 participants
Enrollment target
1
Study location

Study Summary

This trial studies how well EMBr Wave technology works in reducing hot flashes in women with a history of breast cancer. Hot flashes are a common symptom experienced by menopausal women. The standard treatment for hot flashes is hormone replacement therapy, however hormone replacement therapy cannot be used in women with a history of, or active, breast cancer. EMBr Wave is a personal heating and cooling device worn on the wrist. EMBr Wave may help reduce hot flash severity in women with a history of breast cancer.

Primary Outcome

Feasibility will be evaluated primarily with respect to device usage. The proportion of patients who wear the device for at least 8 hours between 8:00 am and 8:00 pm for at least 22 days will be estimated using the entire sample and a 95% Jeffreys interval for binomial proportions will be computed.

Interventions

  • OTHER Questionnaire Administration
  • DEVICE EMBr Wave

Study Locations (1)

Ohio

  • Ohio State University Comprehensive Cancer Center - Columbus

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2020-10-07
Est. Completion 2023-08-24
Phase NA

What the finished NCT05086705 record still lists

NCT05086705 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 770-participant average among 106 other Breast Carcinoma trials with a reported enrollment target (94% lower).

The record links to 4 conditions, with Breast Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Questionnaire Administration is the first listed.

NCT05086705 reports a single indexed study location in Ohio.

Frequently Asked Questions

What is clinical trial NCT05086705 about?

NCT05086705 is a clinical study titled "EMBr Wave for the Reduction of Hot Flashes in Women With a History of Breast Cancer". This trial studies how well EMBr Wave technology works in reducing hot flashes in women with a history of breast cancer. Hot flashes are a common symptom experienced by menopausal women. The standard treatment for hot flashes is hormone replacement therapy, however hormone replacement therapy cannot...

What is the current status of trial NCT05086705?

This trial is currently completed. It is a NA study. The enrollment target is 50 participants. The study started on 2020-10-07. Estimated completion is 2023-08-24.

What conditions does trial NCT05086705 study?

This clinical trial studies the following conditions: Breast Carcinoma, Hot Flashes, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ.

What interventions are being tested in trial NCT05086705?

The interventions under investigation include: Questionnaire Administration (OTHER), EMBr Wave (DEVICE).

Who is sponsoring clinical trial NCT05086705?

This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05086705 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05086705's enrollment target sits among peer trials

50 76th of 106 higher than 28 of 106 other Breast Carcinoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Breast Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00200889 · 50 participants · Early Phase 1

    Mapping Auricular Vagus Nerve Circuitry

  • NCT00409435 · 50 participants · Phase 2

    A Study of Pyridostigmine in Postural Tachycardia Syndrome

  • NCT01202305 · 50 participants

    The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies

  • NCT01225913 · 50 participants · Phase 4

    Mechanism(s) of Airflow Limitation During Exacerbation of Asthma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05086705, the US trial registry maintained by the National Library of Medicine. NCT05086705 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.